摘要
目的探讨纳洛酮治疗慢阻肺并Ⅱ型呼吸衰竭的临床疗效与用药安全性。方法从我院随机选取68例2011年5月~2015年5月收治的慢阻肺并Ⅱ型呼吸衰竭患者,按入院先后顺序分为两组（n=34例）,即常规组给予常规标准治疗,而治疗组则加用纳洛酮治疗,比较其临床疗效及不良反应。结果治疗组临床疗效总有效率（91.18%）明显高于常规组（70.59%）,差异比较有统计学意义（P〈0.05）。两组不良反应发生率差异比较无统计学意义（P〉0.05）。结论纳洛酮治疗慢阻肺并Ⅱ型呼吸衰竭,临床疗效显著,且不增加不良反应,安全有效,可大力推广。
Objective To investigate the clinical efficacy and safety of naloxone in the treatment of chronic obstructive pulmonary disease and respiratory failure. Methods 68 patients with chronic obstructive pulmonary disease and type Ⅱ respiratory failure in our hospital from May 2011 to May 2015 were randomly selected, and divided into two groups（n=34 cases）, a treatment group and a routing group, the routine group received the routing treatment, while the treatment group further received naloxone, the clinical efficacy and adverse reactions between the two groups were compared. Results The total effective rate in treatment group was significantly higher than that in routing group（91.18%）, the difference was statistically significant（P〈 0.05）. There was no significant difference in the incidence of adverse reactions between the two groups（P 〉0.05）. Conclusion Naloxone is effective in treating chronic obstructive pulmonary disease with type Ⅱ respiratory failure, and the clinical effect is significant, and it does not increase the adverse reactions, which is safe and effective.
出处
《中国医药科学》
2016年第3期112-114,共3页
China Medicine And Pharmacy
关键词
纳洛酮
慢阻肺
呼吸衰竭
安全性
Naloxone
Chronic obstructive pulmonary
Respiratory failure
Safety
